Endothelin-1 (ET-1) is a peptide with potent and long-lasting vasoconstrictive properties. Application to exposed blood vessels or direct application to the brain surface or stereotaxic injection into the brain parenchyma results in vasoconstriction, causing downstream ischemia. Using this approach, any area in the brain is more or less targetable. Depending on the concentration of ET-1, the severity and duration of ischemia and the resulting infarct size may change. When the effect of ET-1 weakens, blood flow gradually recovers, resulting in transient focal ischemia. Injection of ET-1 near the middle cerebral artery (MCA) results in lesions comparable to those observed using the middle cerebral artery occlusion (MCAO) technique.
Fig. 1. Intracortical injection of endothelin-1 (ET-1) proximal to the calcarine artery results in transient arterial occlusion. (Teo et al., 2014)
Ace Therapeutics provides standard operating procedures for stereotactic injection of ET-1 near the MCA in animals. Our ET-1 occlusion modeling service provides a reliable and versatile method to simulate focal ischemic stroke. By utilizing the powerful vasoconstrictive properties of ET-1, we can induce controlled and reversible ischemia in targeted brain regions, helping you to study stroke pathophysiology and evaluate potential therapeutic interventions.
We can induce ischemic injury by injecting ET-1 into the superficial cortex of conscious rats through a stereotactic cannula adjacent to the MCA.
To assess compound efficacy, Ace Therapeutics offers a complete range of predictive outcome scores during stroke as well as neurobehavioral tests for monitoring transient and persistent deficits. Examples of complex behavioral tests can be designed upon request and can be combined with appropriate histology and/or neurochemistry to provide a customized assessment package.
We help our clients conduct a variety of studies in ET-1 induced ischemic stroke model, including
Ace Therapeutics guarantees quality data for customizable endothelin-1 (ET-1) induced MCAO model for ischemic stroke. With superior solutions and an experienced team, we are your ideal partner for stroke research. Clients can contact us directly and receive timely feedback.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.